Skip to main content
CYCN logo

Cyclerion Therapeutics, Inc.

CYCNNASDAQHealthcareBiotechnology

$3.36Today:- (-)1Y +57.75%

As of Oct 14, 2026 close

Market cap
$14.28M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.03$36.33
Volume (live)
-
Avg. volume (3M)
54.35K

CYCN was delisted on Oct 24, 2026. Data shown is historical and no longer updated.

Cyclerion Therapeutics (CYCN) Income Statement

Cyclerion Therapeutics reported revenue of $2.07M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 3.7% from $2.00M a year earlier. Cyclerion Therapeutics posted a net loss of $3.53M, compared with a net loss of $3.06M a year earlier. Gross margin was 100.0% and operating margin -239.8%.

Cyclerion Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Cyclerion Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue2.072.000.000.303.322.304.510.000.00
Cost of Revenue0.000.291.325.580.0056.4195.141.531.75
Gross Profit2.072.000.00-5.283.32-54.12-90.63-1.53-1.75
Operating Expenses
Research & Development0.960.291.525.9837.6456.4195.1487.7278.80
Selling, General & Administrative6.095.348.3313.2620.6228.8234.4027.5415.12
Operating Expenses7.055.6312.9513.2658.5228.8234.40115.2593.92
Operating Income-4.97-3.63-12.95-18.54-55.20-82.93-125.04-115.25-93.92
Other Income/Expense
Interest Income0.130.210.360.290.000.302.030.000.00
Interest Expense0.000.000.000.000.020.000.000.000.00
Other Income/Expense1.320.570.360.293.550.292.030.000.00
Income
Income Before Tax-3.53-3.06-12.59-18.25-51.65-77.80-123.01-115.25-93.92
Income Tax Expense0.000.000.000.000.000.000.000.000.00
Net Income-3.53-3.06-5.26-44.08-51.65-77.80-123.01-115.25-93.92
Net Income - Continuous Operations-3.53-3.06-12.59-44.08-51.65-77.80-123.01-115.25-93.92
Net Income - Discontinued Operations--7.33-25.83-----
EBITDA-4.97-3.63-9.58-18.18-53.84-80.64-122.34-113.72-92.18
EBIT-4.97-3.63-9.65-18.54-54.31-82.93---
Depreciation & Amortization0.000.000.070.070.472.302.701.531.75
Earnings Per Share
Basic EPS-1.00-1.00-2.00-20.00-26.00-51.00-88.00-84.00-69.00
Diluted EPS-1.00-1.00-2.00-20.00-26.00-51.00-88.00-84.00-69.00
Basic Shares Outstanding3.182.522.342.171.961.521.371.371.37
Diluted Shares Outstanding3.182.522.342.171.961.521.371.371.37

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cyclerion Therapeutics Financial Statements

What was Cyclerion Therapeutics's revenue in fiscal 2025?

Cyclerion Therapeutics reported revenue of $2.07M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 3.7% from $2.00M a year earlier.

Is Cyclerion Therapeutics profitable?

No. Cyclerion Therapeutics reported a net loss of $3.53M in fiscal 2025. In fiscal 2024 it lost $3.06M.

What is Cyclerion Therapeutics's operating margin?

Cyclerion Therapeutics's operating income was −$4.97M on revenue of $2.07M in fiscal 2025, an operating margin of -239.8%, compared with -181.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition